Abstract
Currently, one of the major focuses in regenerative medicine is the development and implementation into practice of composite biomaterials with chondro- and osteoinductive properties, which include human stem cells and growth factors. Heparin-conjugated fibrinogen was obtained using the carbodiimide method, which was further used to create heparin-conjugated fibrin hydrogels (HCFH). As a result of this work, two types of HCFH were obtained: a hydrogel with encapsulated mesenchymal stem cells (MSC) and a hydrogel with TGF-β1 and BMP-4 growth factors. It has been found that synovial MSCs retain viability after encapsulation in HCFH, which indicates that the developed hydrogel is biocompatible and does not have toxic effect to the cells. The results of enzyme-linked immunosorbent assay on the kinetics of BMP-4 and TGF-β1 release from HCFH showed that the developed hydrogel is able to retain BMP-4 and TGF-β1. The kinetics of release from HCFH into phosphate buffer was significantly slower compared to fibrin hydrogel.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
